Steve Potts, OncoMyx CEO
December 8, 2021 09:03 AM ESTUpdated December 9, 12:11 PM
Deals
Manufacturing

Biotech up­start gets $50M to test new virus-based ther­a­pies against sol­id tu­mors

Josh Sullivan

The team at On­coMyx is try­ing to lever­age one ther­a­peu­tic to treat sev­er­al forms of can­cer, us­ing the Myx­o­ma virus. Wednes­day, it an­nounced the clos­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

Ex­clu­sive: Flag­ship names two CEO-part­ners to lead Va­lo Health, Apri­ori Bio

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times